Orange Book product · Brand (NDA)
VFEND
VORICONAZOLE
At a glance
Dec 19, 2003
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 19, 2003
22 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
VORICONAZOLE
Strength
200MG/5ML
Dosage form
FOR SUSPENSION
Route
ORAL
TE code
AB
Application
NDA 021630
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2017VORICONAZOLEBrand (NDA)
NDA 208562 · HIKMA
- 2002VFENDBrand (NDA)
NDA 021267 · PF PRISM CV
- 2002VFENDBrand (NDA)
NDA 021266 · PF PRISM CV
- 2026VORICONAZOLEGeneric (ANDA)
ANDA 220078 · ZHEJIANG NOVUS
- 2025VORICONAZOLEGeneric (ANDA)
ANDA 220043 · HAINAN POLY PHARM
- 2025VORICONAZOLEGeneric (ANDA)
ANDA 211598 · HETERO LABS LTD V
- 2024VORICONAZOLEGeneric (ANDA)
ANDA 218533 · ASPIRO
- 2024VORICONAZOLEGeneric (ANDA)
ANDA 216805 · ZHEJIANG POLY PHARM
- 2023VORICONAZOLEGeneric (ANDA)
ANDA 211264 · UBI
- 2023VORICONAZOLEGeneric (ANDA)
ANDA 212162 · EUGIA PHARMA
- 2022VORICONAZOLEGeneric (ANDA)
ANDA 210849 · PHARMOBEDIENT
- 2022VORICONAZOLEGeneric (ANDA)
ANDA 214516 · MEITHEAL
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
